OncoCyte Corp
NASDAQ:OCX

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
NASDAQ:OCX
Watchlist
Price: 2.21 USD 0.91%
Market Cap: 37.2m USD
Have any thoughts about
OncoCyte Corp?
Write Note

Operating Margin
OncoCyte Corp

-6 148.5%
Current
-456%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 148.5%
=
Operating Profit
-43.6m
/
Revenue
709k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
OncoCyte Corp
NASDAQ:OCX
36.9m USD
-6 149%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country US
Market Cap 36.9m USD
Operating Margin
-6 149%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.2B USD
Operating Margin
28%
Country US
Market Cap 142B USD
Operating Margin
19%
Country US
Market Cap 115B USD
Operating Margin
38%
Country US
Market Cap 101.6B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.5B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

OncoCyte Corp
Glance View

Market Cap
37.2m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
2.67 USD
Undervaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 148.5%
=
Operating Profit
-43.6m
/
Revenue
709k
What is the Operating Margin of OncoCyte Corp?

Based on OncoCyte Corp's most recent financial statements, the company has Operating Margin of -6 148.5%.